Early Approval for Abbott AIDS Medicine

Article

(ABBOTT PARK, ILL)The Food and Drug Administration (FDA) has granted an early approval of the Abbott Laboratories' AIDS drug Kaletra, a form of protease inhibitor medication that has shown considerable promise in bringing the virus down to undetectable levels. Abbott applied for FDA approval on June 1, 2000 and was not expecting results until later this fall.

Kaletra is a mixture of two drugs, the main one generically called lopinavir and previously called ABT-378 in Abbott clinical labs, the other is ritonavir, already on the market as an AIDS drug under the brand name Norvir. For more information visit www.fda.gov.

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content